DAFNA CAPITAL MANAGEMENT, LLC
Adviser information for DAFNA CAPITAL MANAGEMENT, LLC last updated from Form ADV on March 27th, 2024. Select data displayed; additional Form ADV, Form D, Form 13F and other data is available from the Fincoded API.
Advisory Business
Type of Organization | Limited Liability Company |
---|---|
Fiscal Year End | DECEMBER |
Legal Location | Delaware, United States |
Employees
Total Number of Employees | 8 |
---|---|
Investment Advisory/Research | 7 |
Registered Broker-Dealer Representatives | 0 |
Registered State Investment Advisers | 0 |
Licensed Agents of an Insurance Company | 0 |
No. of Firms/People that Solicit Clients | 0 |
RAUM
Provides Management of Securities Portfolios | Yes |
---|
Type | Accounts | RAUM |
---|---|---|
Discretionary | 4 | $647.9M |
Non-Discretionary | 0 | $0 |
Total | 4 | $647.9M |
Clients
Type | Number | RAUM |
---|---|---|
Individuals | 0 | $0 |
HNW Individuals | 0 | $0 |
Banking or thrift institutions | 0 | $0 |
Investment companies | 0 | $0 |
Business development companies | 0 | $0 |
Pooled investment vehicles | 4 | $647.9M |
Pension and profit sharing plans | 0 | $0 |
Charitable organizations | 0 | $0 |
State or municipal gov entities | 0 | $0 |
Other investment advisers | 0 | $0 |
Insurance companies | 0 | $0 |
Sovereign wealth funds and foreign official institutions | 0 | $0 |
Corporations or other businesses | 0 | $0 |
Other | 0 | $0 |
Type | Number |
---|---|
No. of Non-RAUM Clients | 0 |
No. of Non-U.S. Clients | 25 |
Services
Advisory Services | Portfolio management for pooled investment vehicles |
---|---|
Compensation | % of AUMPerformance-based fees |
Principal Office
10990 WILSHIRE BOULEVARDSUITE 1400
LOS ANGELES
CA
United States
Monday - Friday, 5:30 AM TO 4:00 PM
Tel: 310-954-3200, Fax: 310-445-6594
Chief Compliance Officer
XUN LIN
DIRECTOR OF FINANCE
10990 WILSHIRE BOULEVARD
SUITE 1400
LOS ANGELES
CA
United States
Tel:
310-954-3200
Fax:
310-445-6594
X***@***************M
(Full email address available in API data)
Regulatory Contact
NATHAN FISCHEL
CEO
10990 WILSHIRE BOULEVARD
SUITE 1400
LOS ANGELES
CA
United States
Tel:
310-954-3200
Fax:
310-445-6594
N*******@***************M
(Full email address available in API data)
Industry Affiliates
None |
Private Funds
Name | Type | Assets $USD | Min Investment $USD | No. Owners |
---|---|---|---|---|
DAFNA FUND, L.P. SERIES A | Hedge Fund | $261.9M | $1.0M | 77 |
DAFNA FUND, L.P. SERIES C | Hedge Fund | $142.0M | $1.0M | 21 |
DAFNA INTERNATIONAL FUND LTD. CLASS A | Hedge Fund | $203.1M | $1.0M | 45 |
DAFNA INTERNATIONAL FUND LTD. CLASS C | Hedge Fund | $36.7M | $1.0M | 11 |
DAFNA LIFESCIENCE SELECT, L.P. | Hedge Fund | $179.0M | $1.0M | 3 |
DAFNA LIFESCIENCE, L.P. | Hedge Fund | $468.9M | $1.0M | 3 |
Control Persons
Name | Type | Entity | Title | Since | Ownership |
---|---|---|---|---|---|
FISCHEL, NATHAN | Individual | – | CHIEF EXECUTIVE OFFICER | 02/2000 | < 5% |
GHODSIAN, FARIBA, FISCHEL | Individual | – | CHIEF INVESTMENT OFFICER | 11/2002 | < 5% |
FISCHEL, NATHAN | Individual | THE FISCHEL-GHODSIAN FAMILY TRUST | TRUSTEE | 04/1999 | > 75% |
GHODSIAN, FARIBA, FISCHEL | Individual | THE FISCHEL-GHODSIAN FAMILY TRUST | TRUSTEE | 04/1999 | > 75% |
DAFNA HOLDINGS, L.P. | Domestic Entity | – | MEMBER | 01/2013 | > 75% |
THE FISCHEL-GHODSIAN FAMILY TRUST | Domestic Entity | DAFNA HOLDINGS, L.P. | LIMITED PARTNER | 01/2013 | > 75% |
DAFNA HOLDINGS CORP. | Domestic Entity | DAFNA HOLDINGS, L.P. | GENERAL PARTNER | 01/2013 | |
LIN, XUN | Individual | – | CHIEF COMPLIANCE OFFICER | 11/2017 | < 5% |
DLF1 TRUST | Domestic Entity | DAFNA HOLDINGS, L.P. | LIMITED PARTNER | 06/2021 | 25-50% |
DCF2 TRUST | Domestic Entity | DAFNA HOLDINGS, L.P. | LIMITED PARTNER | 06/2021 | 25-50% |
DSF3 TRUST | Domestic Entity | DAFNA HOLDINGS, L.P. | LIMITED PARTNER | 06/2021 | 25-50% |
GHODSIAN, FARIBA, FISCHEL | Individual | DLF1 TRUST | TRUSTEE | 05/2021 | 25-50% |
GHODSIAN, FARIBA, FISCHEL | Individual | DCF2 TRUST | TRUSTEE | 05/2021 | 25-50% |
GHODSIAN, FARIBA, FISCHEL | Individual | DSF3 TRUST | TRUSTEE | 05/2021 | 25-50% |
No. Employees, Historic
RAUM, Historic
No. Clients, Historic
Holdings
From latest 13F, filed August 14th, 2024 for period ending June 30th, 2024
Name | Class | Value $USD | # Shares | Private Fund |
---|---|---|---|---|
2SEVENTY BIO INC | COMMON STOCK | 4M | 1M | – |
ACCURAY INC | COM | 2M | 1M | – |
ACELYRIN INC | COM | 3M | 694K | – |
ACRIVON THERAPEUTICS INC | COMMON STOCK | 704K | 121K | – |
ADAPTIMMUNE THERAPEUTICS PLC | SPONDS ADR | 333K | 341K | – |
ADC THERAPEUTICS SA | SHS | 645K | 204K | – |
ADICET BIO INC | COM | 726K | 600K | – |
ALECTOR INC | COM | 4M | 913K | – |
ALKERMES PLC | SHS | 3M | 121K | – |
ALLOGENE THERAPEUTICS INC | COM | 1M | 605K | – |
ALTO NEUROSCIENCE INC | COM SHS | 1M | 120K | – |
APREA THERAPEUTICS INC | COM NEW | 558K | 137K | – |
AQUESTIVE THERAPEUTICS INC | COM | 1M | 530K | – |
ARCUS BIOSCIENCES INC | COM | 4M | 253K | – |
ARS PHARMACEUTICALS INC | COM | 2M | 239K | – |
ASCENDIS PHARMA A/S | NOTE 2.250% 4/0 | 4M | – | – |
ASCENDIS PHARMA A/S | SPONSORED ADR | 11M | 81K | – |
ASTRIA THERAPEUTICS INC | COM | 2M | 274K | – |
ATRICURE INC | COM | 15M | 639K | – |
AUTOLUS THERAPEUTICS PLC | SPON ADS | 1M | 347K | – |
AXOGEN INC | COM | 7M | 936K | – |
BICYCLE THERAPEUTICS PLC | SPONSORED ADS | 2M | 122K | – |
BIOCRYST PHARMACEUTICALS INC | COM | 4M | 705K | – |
BIOHAVEN LTD | COM | 8M | 219K | – |
BLUEPRINT MEDICINES CORP | COM | 11M | 105K | – |
BRAINSWAY LTD | SPONSORED ADS | 2M | 298K | – |
CENTESSA PHARMACEUTICALS PLC | SPONSORED ADS | 1M | 123K | – |
CENTURY THERAPEUTICS INC | COM | 4M | 2M | – |
COMPASS PATHWAYS PLC | SPONSORED ADS | 1M | 243K | – |
COMPASS THERAPEUTICS INC | COM | 117K | 117K | – |
COMPUGEN LTD | ORD | 776K | 462K | – |
CYTOKINETICS INC | COM NEW | 22M | 398K | – |
DAY ONE BIOPHARMACEUTICALS I | COM | 9M | 666K | – |
DEXCOM INC | COM | 7M | 66K | – |
EDGEWISE THERAPEUTICS INC | COM | 5M | 290K | – |
FOGHORN THERAPEUTICS INC | COM | 241K | 42K | – |
GALAPAGOS NV | SPON ADR | 3M | 130K | – |
GOSSAMER BIO INC | COM | 1M | 1M | – |
IDEAYA BIOSCIENCES INC | COM | 15M | 422K | – |
IMMATICS NV | SHS | 2M | 145K | – |
IMMUNOVANT INC | COM | 1M | 48K | – |
INOGEN INC | COM | 2M | 209K | – |
INSULET CORP | COM | 3M | 16K | – |
ISHARES NASDAQ BIOTECH INDX | ETF | 14M | 103K | – |
ITEOS THERAPEUTICS INC | COM | 2M | 144K | – |
KALVISTA PHARMACEUTICALS INC | COM | 10M | 807K | – |
KARYOPHARM THERAPEUTICS INC | COM | 167K | 193K | – |
KEROS THERAPEUTICS INC | COM | 3M | 68K | – |
KURA ONCOLOGY INC | COM | 9M | 424K | – |
LARIMAR THERAPEUTICS INC | COM | 5M | 640K | – |
LINEAGE CELL THERAPEUTICS IN | COM | 1M | 1M | – |
MASIMO CORP | COM | 378K | 3K | – |
MEDIWOUND LTD | SHS NEW | 2M | 124K | – |
MERUS N V | COM | 24M | 409K | – |
MINERALYS THERAPEUTICS INC | COM | 1M | 119K | – |
MORPHIC HOLDING INC | COM | 8M | 232K | – |
NEUROCRINE BIOSCIENCES INC | COM | 10M | 72K | – |
NEUROGENE INC | COM | 400K | 11K | – |
NEURONETICS INC | COM | 565K | 314K | – |
NEVRO CORP | COM | 236K | 28K | – |
NYXOAH S A | SHS | 754K | 108K | – |
ORIC PHARMACEUTICALS INC | COM | 255K | 36K | – |
PERSPECTIVE THERAPEUTICS INC | COM NEW | 2M | 232K | – |
POLYPID LTD | COM | 795K | 185K | – |
PROCEPT BIOROBOTICS CORP | COM | 855K | 14K | – |
PROQR THERAPEUTICS N V | SHS EURO | 2M | 906K | – |
REGULUS THERAPEUTICS INC | COM | 2M | 895K | – |
REVOLUTION MEDICINES INC | COM | 20M | 512K | – |
SAGE THERAPEUTICS INC | COM | 1M | 116K | – |
SPDR S&P BIOTECH ETF | ETF | 41M | 445K | – |
SPERO THERAPEUTICS INC | COM | 163K | 125K | – |
STEREOTAXIS INC | COM NEW | 25M | 14M | – |
STOKE THERAPEUTICS INC | COM | 3M | 207K | – |
STRUCTURE THERAPEUTICS INC | SPONSORED ADS | 196K | 5K | – |
SUTRO BIOPHARMA INC | COM | 966K | 330K | – |
SYNDAX PHARMACEUTICALS INC | COM | 13M | 657K | – |
SYROS PHARMACEUTICALS INC | COM NEW | 701K | 136K | – |
TANDEM DIABETES CARE INC | COM NEW | 8M | 204K | – |
TERNS PHARMACEUTICALS INC | COM | 586K | 86K | – |
TOURMALINE BIO INC | COM | 977K | 76K | – |
UROGEN PHARMA LTD | COM | 8M | 469K | – |
VIKING THERAPEUTICS INC | COM | 10M | 189K | – |
XENON PHARMACEUTICALS INC | COM | 11M | 274K | – |